Adjunctive Study of AL-37807 Ophthalmic Suspension

Comparison of Safety and Efficacy of Al-37807 Ophthalmic Suspension vs. Timolol Gel Forming Solution and Vehicle, All Dosed Concomitantly With Xalatan in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00620256

Enrollment

129

Registered

2008-02-21

Start date

2007-11-30

Completion date

2008-07-31

Last updated

2012-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-Angle Glaucoma, Ocular Hypertension

Keywords

Glaucoma, Hypertension

Brief summary

The purpose of the study is to compare the safety and intraocular pressure-lowering efficacy of AL-37807 ophthalmic suspension vs. Timolol gel forming solution vs. AL-37807 vehicle, all dosed concomitantly with Xalatan, in patients with open-angle glaucoma or ocular hypertension.

Interventions

DRUGAL-37807 ophthalmic suspension, 0.1%

DRUGTimolol gel forming solution, 0.5%

OTHERAL-37807 ophthalmic solution vehicle

DRUGLatanoprost ophthalmic solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Open-angle glaucoma * Ocular hypertension * Must have been on Xalatan for at least 3 months * VA not worse than 0.60 * Other protocol-defined inclusion criteria may apply

Exclusion criteria

* Age related * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Mean change from baseline in intraocular pressure	Baseline, up to 4 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026